Target Name: OLFM2
NCBI ID: G93145
Other Name(s): NOE2 | Noelin-2 [Precursor] | Noelin 2 | NOELIN2 | Neuronal olfactomedin related ER localized protein 2 | Noelin-2 | OlfC | Olfactomedin-2 | Olfactomedin 2, transcript variant 2 | NOELIN2_V1 | NOE2_HUMAN | Noelin-2 (isoform 2) | neuronal olfactomedin related ER localized protein 2 | OLFM2 variant 2 | Olfactomedin 2 | olfactomedin 2

OLFM2: A Potential Drug Target for Cancer and Other Diseases

OLFM2 (Nucleotide-Oriented Ligation Mapping) 2 is a highly promising drug target and biomarker for various diseases, including cancer. OLFM2 is a gene expression regulator that plays a crucial role in cell growth, differentiation, and apoptosis. Mutations in the OLFM2 gene have been linked to various human diseases, including cancer.

OLFM2 functions as a negative regulator of the TGF-β signaling pathway. The TGF-β pathway is a well-known signaling pathway that regulates cellular growth, differentiation, and survival. It is composed of several transcription factors, including SMAD1, SMAD4, and TGF-β1. The TGF-β pathway plays a crucial role in the development and progression of cancer, as well as in the regulation of cellular processes such as cell growth, apoptosis, and angiogenesis.

OLFM2 is a key regulator of the TGF-β pathway. It consists of a nucleotide-binding oligomerization domain (NBD), a nucleotide-binding oligomerization domain (NBD), and a C-terminal TGF-β-responsive domain. The NBDs are responsible for the formation of the oligomerization complex, while the C-terminal domain is responsible for the interaction with TGF-β1.

Mutations in the OLFM2 gene have been linked to various human diseases, including cancer. For example, studies have shown that mutations in the OLFM2 gene are associated with the development of various types of cancer, including breast, ovarian, and colorectal cancers. In addition, overexpression of the OLFM2 gene has been shown to promote the growth and survival of cancer cells, highlighting its potential as a drug target.

OLFM2 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and angiogenesis. For example, studies have shown that OLFM2 is involved in the regulation of cell proliferation and survival in various cell types, including cancer cells. In addition, OLFM2 has been shown to play a role in the regulation of cell death, as well as in the regulation of angiogenesis.

The OLFM2 gene has also been shown to be involved in the regulation of cellular signaling pathways. For example, studies have shown that OLFM2 is involved in the regulation of theNotch signaling pathway, a well-known signaling pathway that regulates cellular processes such as stem cell maintenance and differentiation. In addition, OLFM2 has been shown to play a role in the regulation of the Wnt signaling pathway, a signaling pathway that plays a crucial role in the development and maintenance of tissues.

OLFM2 has also been shown to be involved in the regulation of cellular immune responses. For example, studies have shown that OLFM2 is involved in the regulation of T cell development and function, as well as in the regulation of immune cell responses to infection.

In conclusion, OLFM2 is a highly promising drug target and biomarker for various diseases, including cancer. Its role as a negative regulator of the TGF-β signaling pathway makes it an attractive target for small molecules and other therapeutic agents that can modulate its activity. Furthermore, its involvement in various cellular processes, including cell growth, apoptosis, and angiogenesis, as well as its involvement in the regulation of cellular signaling pathways and immune responses, make it an attractive target for the development of new therapeutic approaches.

Protein Name: Olfactomedin 2

Functions: Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation. TGF-beta induces expression and translocation of OLFM2 to the nucleus where it binds to SRF, causing its dissociation from the transcriptional repressor HEY2/HERP1 and facilitating binding of SRF to target genes (PubMed:25298399). Plays a role in AMPAR complex organization (By similarity). Is a regulator of vascular smooth-muscle cell (SMC) phenotypic switching, that acts by promoting RUNX2 and inhibiting MYOCD binding to SRF. SMC phenotypic switching is the process through which vascular SMCs undergo transition between a quiescent contractile phenotype and a proliferative synthetic phenotype in response to pathological stimuli. SMC phenotypic plasticity is essential for vascular development and remodeling (By similarity)

More Common Targets

OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P